novocure(NVCR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, representing an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Adjusted EBITDA was negative $34 million for the full year, with a guidance of -$20 million to break even for 2026 [21][23] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company expects contributions from new indications, including Optune Lua and Optune Pax, to be in the range of $15 million to $25 million for 2026 [19][29] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the U.S. saw a 4% growth [11] - The company anticipates modest contributions from new market launches in Spain, Czechia, and British Columbia [12] Company Strategy and Development Direction - The company aims to drive profitability and has set a goal to reach adjusted EBITDA breakeven in 2026 [23][56] - The recent approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Optune products and the importance of establishing coverage policies with payers [49] - The company is focused on maintaining momentum and achieving regulatory, clinical, and commercial milestones in 2026 [7][55] Other Important Information - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] - Dr. Nicolas Leupin resigned as Chief Medical Officer, and Dr. Uri Weinberg will assume the role, combining scientific and clinical organizations to enhance R&D execution [9] Q&A Session Summary Question: Why is the company providing guidance now? - Management indicated that setting clear expectations for growth is essential as the company matures in the public market [27][28] Question: What are the assumptions behind the revenue guidance? - The guidance includes growth from established GBM markets, new markets, and contributions from new indications [29][30] Question: How will Optune Pax be prescribed based on the approved label? - The company plans to target a highly motivated patient population with limited treatment options, emphasizing the unique value proposition of Optune Pax [39] Question: How much sales force is allocated for Optune Pax? - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44]